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Objectives. To analyse consecutive patients with RA in usual rheumatology care between 1980 and 2004at two settings for the proportion of
patients taking MTX, interval from patient presentation to MTX prescription and radiographic and functional status outcomes.
Methods. Longitudinal study of all patients seen in usual care between 1980 and 2004, 1982 consecutive patients in Jyva ¨skyla ¨, Finland and
738 consecutive patients in Nashville, TN, USA. Clinical status was assessed as Larsen radiographic scores in Jyva ¨skyla ¨ and modified health
assessment questionnaire (MHAQ) in Nashville.
Results. The probability of initiating MTX within 5 yrs after presentation increased from <5% in Jyva ¨skyla ¨ before 1989 to >90% in 2000–04,
and from 25% in Nashville in 1980–84 to >90% since 1995. The median interval from presentation to MTX initiation in Jyva ¨skyla ¨ was 14 yrs in
1980–84 vs 8.6 in 1985–89, 4.5 in 1990–94, 1.8 in 1995–99 and <1yr in 2000–05; in Nashville, median intervals were 8.6 yrs in 1980–84, 4.4
years in 1985–89, and <2 months in 1990–95, 1995–2000 and 2000–05. Patient outcomes were substantially improved in both settings: in
Jyva ¨skyla ¨, mean 5-yr Larsen radiographic scores (0–100) were 15.7 in 1980–84 vs 4.0 in 1995–99; in Nashville, mean MHAQ scores (0–3)
for physical function were 1.13 in 1980–84 vs 0.57 in 2000–04.
Conclusion. Early MTX in usual clinical care of RA increased from <5% in 1980 to >90% in 2004. Over this period, substantially improved
outcomes were seen, most of which antedated biological agents.
KEY WORDS: Rheumatoid arthritis, Health assessment questionnaire, Modified health assessment questionnaire, Methotrexate, Outcomes.
Introduction
Three major advances in treatment of RA over the last two
decades include: (i) early intervention toward ‘tight control’ of
inflammation to prevent joint damage [1–3]; (ii) emergence of
weekly low-dose MTX as the ‘anchor drug’ for RA [4–6]; and
(iii) targeted therapies with biological agents [7–9]. MTX provides
substantially greater efficacy [4, 5, 10–12], effectiveness [13–17],
tolerability [18, 19] and lower toxicity [13, 14, 20] than previously
available DMARDs. Significantly better outcomes are seen at this
time compared with earlier periods [16, 17, 21–25].
Recent medical literature concerning RA has been dominated
by targeted biological agents. The ascendancy of early treatment
with weekly low-dose MTX for RA over the past 25 yrs remains
relatively under-recognized [26]. Biological agents are a major
advance, taken by 20–50% of the patients with RA at aggressive
treatment centres, and fewer at other sites [27]. Nonetheless, MTX
remains the most widely prescribed medication for RA at this
time. However, many non-rheumatologists continue to regard
potential risks of weekly low-dose MTX for rheumatic disease as
similar to those of high-dose MTX (as an anti-neoplastic agent),
and may discontinue its use for relatively minor liver function
abnormalities or for elective surgery, with frequent deleterious
effects.
This report examines three phenomena concerning MTX use
over 25 yrs from 1980 to 2004 in 1982 RA patients in Jyva ¨ skyla ¨ ,
Finland and 738 RA patients seen by T.P. in Nashville, TN, USA:
(i) the proportion of patients taking MTX; (ii) the interval from
patient presentation to prescription; and (iii) radiographic and
functional status outcomes.
Patients and methods
A database has been maintained on all patients with RA seen at
Jyva ¨ skyla ¨ Central Hospital, Jyva ¨ skyla ¨ , Finland [28], and all
patients seen by TP at Vanderbilt University in Nashville, TN,
USA [20] since 1980.
Jyva ¨ skyla ¨ Central Hospital is the only rheumatology centre in
the Central Finland Health Care District and serves a population
of 265 000. All new patients with suspected RA are referred to this
clinic for diagnosis and therapy. Most patients with persistent RA
continue their care at this hospital with regular visits to outpatient
and day-care clinics. The Central Finland RA Database includes
demographic and clinical data on patients with RA who have been
seen in Jyva ¨ skyla ¨ Central Hospital since 1980. This database was
begun in 1995 with retrospective entry of data collected at all clinic
visits of all RA patients seen from 1980 to 95 and ongoing entry of
data collected at all visits of RA patients since 1995 [29]. The
Jyva ¨ skyla ¨ patients provide a true inception cohort, as all patients
are seen for their first visit with RA prior to any long-term
treatment.
The Vanderbilt weekly academic rheumatology clinic of TP in
Nashville is a US university site. This database was begun in 1989
with retrospective entry of data collected at all clinic visits of
all patients seen from 1980 to 1989, and ongoing entry of data
collected at all clinic visits since 1989. Most of the Nashville
patients were seen prior to long-term treatment of RA, but some
patients were seen for their first visit after having been treated by
other physicians, including other rheumatologists in other areas.
Fewer than 20 patients had prior treatment with MTX, none prior
to 1995.
The databases contain demographic data, standard rheumatol-
ogy measures including joint counts, radiographs, laboratory
measures and patient questionnaires. In Jyva ¨ skyla ¨ , the outcome
measure available in most patients since 1980 is a radiograph,
which is taken at baseline and during follow-up 5 yrs after the
diagnosis. In Nashville, the outcome measure available in most
patients since 1980 is a modified health assessment questionnaire
(MHAQ) [30] and successor multidimensional HAQ (MDHAQ)
[31], which includes all items in the MHAQ. All patients since
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visits; therefore, scores for physical function and a visual analogue
scale (VAS) for pain are available to compare status over time in
all patients.
Previous reports from these two sites have indicated improved
outcomes in some of these patients [24, 25]. This report includes
new analyses concerning therapies with MTX and other
DMARDs, and extends previous analyses to the entire databases
from 1980 to 2004. The interval between patient presentation and
initiation of MTX, as monotherapy or in combination with other
medications, was calculated and presented separately for each site
for five different 5-yr periods between1980 and 2004, including
1980–84, 1985–90, 1990–94, 1995–99 and 2000–04, using Kaplan–
Meier statistics.
The percentage of patients who were taking MTX as the first
DMARD was computed. In the Jyva ¨ skyla ¨ cohort, radiographs
taken 5 (3.5–6.5) yrs after patient presentation were scored
according to the Larsen method (0–100) [32, 33]. In the Nashville
cohort, the last MHAQ (0–3) and pain VAS (0–10) values of each
patient were scored in the period in which the patient was
first seen. Data concerning each patient are included in only one
of the 5-yr periods reported.
Data were computed as mean, S.D., median and interquartile
range for continuous variables, and as percentages for dichot-
omous variables. The mean and 95% CI values for Larsen scores,
MHAQ and pain were calculated.
Results
Patient characteristics
Patients from Jyva ¨ skyla ¨ had a mean age of 55 yrs; 67% were
females and 62% were positive for RF (Table 1). Patients in
Nashville were quite similar, with a mean age of 54 yrs, while 61%
were females and 63% RF-positive. Patients in the two cohorts
differed in median duration of symptoms at first visit, which was
6 months in Jyva ¨ skyla ¨ and 4 yrs in Nashville, reflecting different
referral patterns at the two sites.
Interval after presentation until treatment with MTX
In Jyva ¨ skyla ¨ , the median interval from presentation to initiation
of MTX fell from 14 yrs in 1980–84 to 8.6 yrs in 1985–89, 4.5 yrs
in 1990–94, 1.8 yrs in 1995–99 and <1yr in 2000 (Table 1, Fig. 1).
In Nashville, the median interval fell from 8.6 yrs in 1980–84 to
4.4 yrs in 1985–89 to <2 months in the three 5-yr periods
beginning in 1990 (Table 1, Fig. 1). The probability of starting
MTX by 5 yrs after presentation increased from <5% in
Jyva ¨ skyla ¨ in 1984–89 to 50% in 1990–94 and >90% in 2000–04,
and from 25% in Nashville in 1984–89 to >50% in 1985–89,
>80% in 1990–94 and >90% since 1995 (Fig. 1).
The first DMARD used in the highest number of patients in
1980–84at both sites was intramuscular gold (Table 2). However,
use of intramuscular gold as the first DMARD declined from
63.5% to 0.2% in Jyva ¨ skyla ¨ , and from 27.3% to 1.5% in
Nashville, between 1980–84 and 2000–04. The proportion of
patients who took MTX as the first DMARD increased from 0%
to 31% in Jyva ¨ skyla ¨ and from 10% to 78% in Nashville between
1980 and 2004 (Table 2).
Clinical status in patients seen at different periods
In Jyva ¨ skyla ¨ , clinical outcome over the years was analysed accord-
ing to Larsen radiographic score 5 yrs after onset of disease. The
mean score fell from 15.7 in 1980–84 to 11.0 in 1985–89, was
level at 11.7 from 1990–94, but with further decline in 1995–99
to 4.0 (5-yr radiographs were not available after 2000) (Fig. 2).
In Nashville, clinical outcomes were assessed according to the
MHAQ scores for physical function and pain. Mean scores for
physical function (0–3) declined from 1.13 in 1980–84 to 1.04 in
1985–89, 0.91 in 1990–94, 0.75 in 1995–99 and 0.57 in 2000–04
(Fig. 3a). A similar decline in last mean pain (0–10) score was also
seen, from 5.9 in 1980–84 to 4.9 in 1985–89, 5.0 in 1990–94, 4.9
in 1995–99 and 3.8 in 2000–04 (Fig. 3b). These results were
seen although the disease duration at final visit was increased from
11.5 yrs in 1980–84 to 14.5 yrs in 2000–04 (data not shown).
Discussion
This report presents five observations in patients with RA over 25
yrs from 1980 to 2005at two sites in Finland and Tennessee: (i)
weekly, low-dose MTX has replaced intramuscular gold injections
as the primary therapy for RA, taken by >90% of the patients; (ii)
MTX has been used at progressively shorter intervals after
presentation, to the point where it is prescribed within a month of
presentation at these sites; (iii) shortening of the interval from
diagnosis to initiation of MTX at the US site antedated the
Finnish site by about a decade; (iv) these changes have coincided
with substantially improved radiographic outcomes in Finland
and functional outcomes in Nashville; and (v) the improved
outcomes seen in most of these patients antedated availability of
biological agents for RA.
Several limitations are seen in this study. The most important
limitation is that improved patient outcomes over the 25-yr period
cannot be attributed definitively to early treatment with MTX, as
improved outcomes could result in part or entirely from other
developments including a secular trend towards milder disease
TABLE 1. Characteristics of patients at two sites, one in Finland and one in the United States, in 5-yr periods from 1980 to 2004
Period of the first visit 1980–1984 1985–1989 1990–1994 1995–1999 2000–2004 Total
Jyva ¨skyla ¨, Finland
Number of patients 219 305 363 508 497 1892
Age, mean (S.D.), yrs 50 (15) 53 (15) 55 (16) 57 (15) 58 (16) 55 (16)
Female (%) 69 64 67 66 69 67
RF-positive (%) 74 76 66 57 51 62
Duration of symptoms, median (IQR) at presentation, months 9 (5, 23) 6 (4, 12) 6 (3, 14) 5 (3, 12) 5 (3, 11) 6 (3, 12)
Total follow-up, median (IQR), yrs 16 (12, 20) 12 (6, 15) 7 (3, 11) 5 (4, 7) 2 (1, 2) 5 (2, 10)
Median number of years from presentation
to initiation of MTX, cumulative percentage (95% CI)
14 (12, 16) 8.6 (7.6, 9.6) 4.5 (3.7, 5.3) 1.8 (1.5, 2.2) 0.5 (0.3, 0.7) 4.4 (3.9, 5.0)
Nashville, TN, USA
Number of patients 216 185 141 93 103 738
Age, mean (S.D.), yrs 55 (15) 54 (14) 53 (15) 54 (12) 54 (15) 54 (14)
Female (%) 69 73 70 68 72 71
RF-positive (%) 69 58 59 60 70 63
Duration of disease, median (IQR) at presentation, yrs 5 (1, 12) 4 (1, 13) 3 (1, 8) 3 (1, 11) 6 (1, 12) 4 (1, 12)
Total follow-up, median (IQR), yrs 4.2 (0.1, 10) 3.8 (0.3, 7.9) 1.3 (0.2, 7.6) 3.1 (0.1, 5.8) 0.7 (0.2, 2.0) 2.2 (0.1, 6.9)
Median number of years from presentation to initiation of MTX,
cumulative percentage (95% CI)
8.6 (7.5, 9.6) 4.4 (2.9, 5.9) 0.2 (0, 0.3) 0.1 (0.1, 0.2) 0 (0, 0) 1.6 (1.0, 2.2)
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(so that the relative proportion of severe patients is falling) and
improved general health and care in the community beyond
specific treatment for RA. Nonetheless, data in patients with RA
from 22 countries in 2005–06 indicate high disease activity levels in
many countries at this time, associated with lesser use of MTX
and other DMARDs [27]. Therefore, it appears likely that early
treatment with MTX may play at least some role in improved
outcomes.
A second limitation is that it might appear ideal to document
long-term effectiveness of weekly low-dose MTX in randomized
controlled clinical trials. However, long-term clinical trials over 5–
10 yrs in a symptomatic disease such as RA cannot be performed
for logistic and ethical reasons [36], particularly with documenta-
tion of the efficacy of aggressive vs traditional therapy of RA in
randomized controlled clinical trials [37–39].
Third, it would be ideal if the entire core data set were available
from each patient at each visit. However, data concerning
radiographs and MHAQ appear representative of two major
indicators of RA progression and these may be the ‘best available’
data over the 25-yr period.
Fourth, the study includes only two sites. However, few settings
have available clinical data concerning therapies taken by
consecutive patients over 25 yrs. The unusual databases from
Jyva ¨ skyla ¨ , Finland and by T.P. in Nashville, TN, USA, provided
an opportunity to document changes in MTX therapy over the
years. The similarity of results from the two sites and similarity
at this time to many sites in many countries [40] suggest that the
observations may be at least in part generalizable, although there
are sites with lesser use of MTX at this time.
MTX courses were reported in 1992 to be continued over at
least 5 yrs in >50% of the patients, in marked contrast to 10–20%
FIG. 1. Interval between patient presentation and initiation of MTX in Jyva ¨skyla ¨, Finland and Nashville, TN, according to the period of patient presentation.
TABLE 2. The first DMARD for RA in Jyva ¨skyla ¨, Finland and the first DMARD at presentation in Nashville, TN, USA, per 5-yr period since 1980
1980–1984 1985–1989 1990–1994 1995–1999 2000–2004
Jyva ¨skyla ¨,Finland
Number of patients 219 305 363 508 497
Intramuscular gold, n (%) 139 (63.5) 171 (56.1) 51 (14.0) 12 (2.4) 1 (0.2)
HCQ, n (%) 72 (32.9) 35 (11.5) 29 (8.0) 44 (8.7) 70 (14.1)
SSZ, n (%) 2 (0.9) 92 (30.2) 257 (70.8) 366 (72.0) 257 (51.7)
MTX, n (%) 0 0 1 (0.3) 66 (13.0) 88 (17.7)
MTX in combination, n (%) 0 0 14 (3.9) 11 (2.2) 66 (13.3)
Other, n (%) 0 3 (3.0) 8 (2.2) 4 (0.8) 7 (1.4)
No medication, n (%) 6 (2.7) 4 (1.3) 3 (0.8) 5 (1.0) 8 (1.6)
Nashville, TN, USA
Number of patients 216 185 141 93 103
Intramuscular gold, n (%) 59 (27.3) 18 (8.9) 5 (3.5) 3 (2.3) 1 (1.5)
HCQ, n (%) 23 (10.6) 12 (6.5) 25 (17.7) 10 (10.8) 4 (3.9)
Auranofin, n (%) 9 (4.2) 30 (16.2) 7 (5.0) 0 0
AZA, n (%) 11 (5.1) 6 (3.2) 2 (1.4) 0 1 (1.0)
MTX, n (%) 21 (9.7) 48 (25.9) 77 (54.6) 58 (62.4) 68 (66.0)
MTX in combination, n (%) 1 (0.5) 0 3 (2.1) 8 (8.6) 12 (11.7)
LEF, n (%) 0 0 0 1 (1.1) 3 (2.9)
Biological agent, n (%) 0 0 0 1 (1.1) 6 (5.8)
Other, n (%) 7 (3.2) 8 (4.3) 2 (1.4) 0 1 (1.0)
Prednisone only, n (%) 29 (13.4) 29 (15.7) 16 (11.3) 10 (10.8) 6 (5.8)
No medication, n (%) 56 (25.9) 34 (18.4) 4 (2.8) 2 (2.2) 1 (1.0)
Ascendancy of MTX in RA 1545of courses of parenteral gold, penicillamine, HCQ and AZA,
which were continued at 5 yrs [14]. These data were interpreted to
suggest that patients found that MTX provided greater long-term
effectiveness, lesser long-term toxicity and the absence of loss of
efficacy seen with traditional DMARDs [14]. More recently, MTX
was found to be continued by 80% of the patients at 5 yrs in the
Nashville clinic of T.P. between 1990 and 2003 [20].
MTXwasintroducedin1951asananti-neoplasticagent[41,42].
In high doses, it is a cytotoxic agent with substantial potential
toxicity and low tolerability. However, weekly low-dose MTX, as
used in treatment of RA, appears to act primarily as an effective
and very well-tolerated anti-inflammatory agent [43]. Weekly low-
dose MTX in RA may be one of the best available medications for
any chronic disease at this time, rivalling insulin and proton pump
inhibitors in being continued by most patients over the years as a
result of effectiveness, tolerability and safety. Nonetheless,
clinicians and patients often do not distinguish between high-dose
MTX used to treat neoplastic disease and weekly low-dose MTX,
and often discontinue its use unnecessarily, e.g. around elective
surgery, with deleterious effects for the patient.
The effectiveness and low toxicity of weekly, low-dose MTX
remain under-recognized. Indeed, with the use of MTX, many
patients with RA do not develop significant joint damage at this
time, as indicated in low radiographic scores in Finland [24] and
Nashville [25]. Work disability rates [44] and mortality rates
appear to be falling, associated with good response to therapies
including MTX [16, 17]. These data indicate a major change in
outcomes of RA associated with widespread use of MTX.
In conclusion, we have documented a substantial increase in
proportion of patients treated and time to treatment of patients
with RA with MTX over a 25-yr period at two sites, one in
Finland and one in the United States. At this time, most patients
are treated with MTX within the first year of disease, if not within
the first few months, as the ‘anchor drug’ for treatment of RA, at
least at these two sites, and many other sites. Evidence of
substantially improved patient status was seen over the 25 yrs,
although this clinical improvement may have resulted from other
causes than early treatment with MTX.
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 Ascendancy of MTX from 1980 to 2005 occurred about 10 yrs
earlier in the United States than Finland.
 MTX is associated with improved long-term outcomes of RA.
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